All In Biotech

Drug Trial Radar · NCT01553591

Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome

Last checked: Nov 20, 2026Latest source record: Sep 4, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,282 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,282

Actual

Start

May 29, 2012

Primary completion

Jul 29, 2014

Study completion Jul 29, 2014

Sponsor

Lead sponsor
Furiex Pharmaceuticals, IncIndustry
Sponsor type
Industry
First posted
Mar 14, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of eluxadoline (JNJ-27018966) compared with placebo in the treatment of participants with diarrhea-predominant irritable bowel syndrome.

Conditions

  • Irritable Bowel Syndrome

Interventions

  • EluxadolineDrug

    Oral tablets twice daily

  • PlaceboDrug

    Oral tablets twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain And Daily Stool Consistency ScoresTime frame: Up to 12 Weeks

Locations

283 sites in 3 countries. Site status is shown where the registry gives one.

  • Furiex Research Site

    Athens, Alabama

  • Furiex Research Site

    Birmingham, Alabama

  • Furiex Research Site

    Foley, Alabama

  • Furiex Research Site

    Huntsville, Alabama

  • Furiex Research Site

    Ozark, Alabama

  • Furiex Research Site

    Chandler, Arizona

  • Furiex Research Site

    Glendale, Arizona

  • Furiex Research Site

    Mesa, Arizona

  • Furiex Research Site

    Phoenix, Arizona

  • Furiex Research Site

    Tucson, Arizona

  • Furiex Research Site

    Little Rock, Arkansas

  • Furiex Research Site

    Little Rock, Arkansas

  • Furiex Research Site

    North Little Rock, Arkansas

  • Furiex Research Site

    Azusa, California

  • Furiex Research Site

    Bell Gardens, California

  • Furiex Research Site

    Beverly Hills, California

  • Furiex Research Site

    Carson, California

  • Furiex Research Site

    Chula Vista, California

  • Furiex Research Site

    Corona, California

  • Furiex Research Site

    El Cajon, California

  • Furiex Research Site

    Encino, California

  • Furiex Research Site

    Garden Grove, California

  • Furiex Research Site

    Lomita, California

  • Furiex Research Site

    Los Angeles, California

  • Furiex Research Site

    Monterey Park, California

  • Furiex Research Site

    Murrieta, California

  • Furiex Research Site

    Newport Beach, California

  • Furiex Research Site

    North Hollywood, California

  • Furiex Research Site

    Oakland, California

  • Furiex Research Site

    Oxnard, California

  • Furiex Research Site

    Pismo Beach, California

  • Furiex Research Site

    Poway, California

  • Furiex Research Site

    Riverside, California

  • Furiex Research Site

    Roseville, California

  • Furiex Research Site

    Sacramento, California

  • Furiex Research Site

    San Diego, California

  • Furiex Research Site

    San Diego, California

  • Furiex Research Site

    Santa Monica, California

  • Furiex Research Site

    Thousand Oaks, California

  • Furiex Research Site

    Colorado Springs, Colorado

Showing 40 of 283 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.